Twist Bioscience
JP Morgan Healthcare Conference, Day 1: Oxford Nanopore, 10x Genomics, Bruker, Qiagen, More
Highlights from the first day included Exact Sciences' plan to launch three new cancer tests in 2025 and Qiagen's sample prep launch plans for 2026.
Wolfe Research Begins Coverage of Hologic at Peer Perform, Tempus and Twist Bioscience at Outperform
Analyst Doug Schenkel said that Tempus has a broad and growing menu and Twist Bio has developed a novel DNA synthesis platform. He set $60 price targets for those companies.
Twist Bioscience Fiscal Q4 Revenues Jump 27 Percent
The South San Francisco, California-based firm booked $84.7 million in revenues for fiscal Q4 revenues and $313.0 million for FY 2024, both record numbers for the company.
New Products Posted to GenomeWeb: Twist Bioscience, Nonacus, Inocras, DNAStar, More
New products and services recently posted on GenomeWeb.
Twist Bioscience Signs $15M Royalty Purchase Agreement With Xoma Royalty
Xoma will pay $15 million in cash for rights to half of Twist's milestone and royalty payments from existing antibody discovery and biopharma collaborations.
Oct 21, 2024